 Seena Aisner
Concepts (270)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 1 | 2022 | 47 | 0.740 |
Why?
| | Soft Tissue Neoplasms | 5 | 2009 | 110 | 0.610 |
Why?
| | Bone Neoplasms | 4 | 2008 | 229 | 0.500 |
Why?
| | Thymus Neoplasms | 3 | 2011 | 22 | 0.480 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2017 | 1050 | 0.480 |
Why?
| | Diagnosis, Differential | 10 | 2022 | 1434 | 0.460 |
Why?
| | Lung Neoplasms | 10 | 2017 | 2344 | 0.420 |
Why?
| | Octreotide | 2 | 2010 | 27 | 0.390 |
Why?
| | Sarcoma, Alveolar Soft Part | 2 | 2010 | 6 | 0.380 |
Why?
| | Liposarcoma | 3 | 2009 | 26 | 0.380 |
Why?
| | Breast Neoplasms | 3 | 2022 | 2104 | 0.380 |
Why?
| | Prednisone | 2 | 2010 | 234 | 0.360 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2010 | 155 | 0.360 |
Why?
| | Lipoma | 2 | 2009 | 15 | 0.360 |
Why?
| | Translocation, Genetic | 3 | 2010 | 92 | 0.350 |
Why?
| | Receptor, ErbB-2 | 3 | 2010 | 325 | 0.340 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2010 | 35 | 0.330 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2010 | 63 | 0.330 |
Why?
| | Chondroblastoma | 2 | 2006 | 3 | 0.310 |
Why?
| | Biopsy, Fine-Needle | 4 | 2014 | 67 | 0.300 |
Why?
| | ErbB Receptors | 3 | 2016 | 605 | 0.300 |
Why?
| | Fibula | 1 | 2008 | 47 | 0.290 |
Why?
| | Biomarkers, Tumor | 5 | 2017 | 1161 | 0.290 |
Why?
| | Nevus, Spindle Cell | 1 | 2007 | 1 | 0.280 |
Why?
| | Angiofibroma | 1 | 2007 | 6 | 0.280 |
Why?
| | Leiomyoma | 1 | 2008 | 73 | 0.270 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2006 | 10 | 0.260 |
Why?
| | Tibia | 1 | 2008 | 172 | 0.260 |
Why?
| | Femoral Neoplasms | 1 | 2006 | 10 | 0.250 |
Why?
| | Head and Neck Neoplasms | 2 | 2012 | 544 | 0.250 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 184 | 0.240 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2017 | 957 | 0.240 |
Why?
| | Image Enhancement | 1 | 2006 | 168 | 0.240 |
Why?
| | Cheek | 1 | 2004 | 15 | 0.230 |
Why?
| | Facial Neoplasms | 1 | 2004 | 18 | 0.230 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2016 | 88 | 0.220 |
Why?
| | Immunohistochemistry | 10 | 2014 | 1690 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2017 | 1560 | 0.210 |
Why?
| | Microtomy | 1 | 2003 | 4 | 0.210 |
Why?
| | Cytological Techniques | 1 | 2003 | 27 | 0.200 |
Why?
| | Biopsy, Needle | 1 | 2003 | 187 | 0.200 |
Why?
| | Pain | 2 | 2008 | 791 | 0.200 |
Why?
| | Vulvar Neoplasms | 1 | 2022 | 12 | 0.190 |
Why?
| | Subcutaneous Tissue | 1 | 2022 | 22 | 0.190 |
Why?
| | Middle Aged | 25 | 2019 | 31177 | 0.190 |
Why?
| | Paclitaxel | 2 | 2014 | 218 | 0.180 |
Why?
| | Hypothalamus | 1 | 2022 | 148 | 0.180 |
Why?
| | Breast | 1 | 2022 | 140 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3397 | 0.180 |
Why?
| | Chromosomes, Human, Pair 11 | 2 | 2010 | 56 | 0.160 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2010 | 307 | 0.160 |
Why?
| | Vulva | 2 | 2022 | 24 | 0.150 |
Why?
| | Skin Neoplasms | 1 | 2006 | 830 | 0.150 |
Why?
| | Humans | 38 | 2022 | 129847 | 0.150 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 147 | 0.150 |
Why?
| | Aged | 19 | 2019 | 22107 | 0.150 |
Why?
| | Thymoma | 2 | 2011 | 33 | 0.140 |
Why?
| | Female | 27 | 2022 | 68829 | 0.140 |
Why?
| | Male | 26 | 2017 | 63759 | 0.140 |
Why?
| | Selenium | 2 | 2017 | 36 | 0.140 |
Why?
| | Urinary Bladder | 1 | 2019 | 176 | 0.130 |
Why?
| | Bevacizumab | 1 | 2017 | 128 | 0.130 |
Why?
| | Erlotinib Hydrochloride | 1 | 2016 | 70 | 0.130 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 32 | 0.130 |
Why?
| | Disease-Free Survival | 4 | 2013 | 647 | 0.130 |
Why?
| | Adult | 18 | 2017 | 35634 | 0.130 |
Why?
| | Anilides | 1 | 2016 | 70 | 0.130 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2019 | 226 | 0.130 |
Why?
| | Neoplasm Staging | 4 | 2017 | 1282 | 0.130 |
Why?
| | Carcinoma | 2 | 2011 | 213 | 0.130 |
Why?
| | Sputum | 1 | 2017 | 302 | 0.120 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 181 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2013 | 1327 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2014 | 232 | 0.110 |
Why?
| | Isotretinoin | 1 | 2014 | 23 | 0.110 |
Why?
| | DNA Methylation | 2 | 2017 | 606 | 0.110 |
Why?
| | Angiomatosis | 1 | 2013 | 4 | 0.110 |
Why?
| | Breast Diseases | 1 | 2013 | 22 | 0.110 |
Why?
| | Polyps | 1 | 2013 | 11 | 0.110 |
Why?
| | Vulvar Diseases | 1 | 2013 | 9 | 0.110 |
Why?
| | Adenoma, Oxyphilic | 1 | 2013 | 6 | 0.110 |
Why?
| | Receptors, Prostaglandin E, EP3 Subtype | 1 | 2013 | 2 | 0.100 |
Why?
| | Receptors, Prostaglandin E, EP4 Subtype | 1 | 2013 | 5 | 0.100 |
Why?
| | Genes, ras | 1 | 2013 | 95 | 0.100 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2013 | 40 | 0.100 |
Why?
| | Hyperplasia | 1 | 2013 | 175 | 0.100 |
Why?
| | Pyridines | 1 | 2016 | 478 | 0.100 |
Why?
| | Interferon-alpha | 1 | 2014 | 194 | 0.100 |
Why?
| | Immunoenzyme Techniques | 3 | 2016 | 211 | 0.100 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2010 | 24 | 0.100 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2009 | 66 | 0.100 |
Why?
| | Smad Proteins | 1 | 2012 | 40 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 2 | 2009 | 63 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2013 | 357 | 0.090 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 19 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 628 | 0.090 |
Why?
| | Pneumonectomy | 3 | 2017 | 151 | 0.090 |
Why?
| | Autophagy | 1 | 2013 | 266 | 0.090 |
Why?
| | Carboplatin | 1 | 2011 | 139 | 0.090 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 886 | 0.090 |
Why?
| | Chromosomes, Human, X | 1 | 2010 | 69 | 0.080 |
Why?
| | Lipid Metabolism | 1 | 2013 | 503 | 0.080 |
Why?
| | World Health Organization | 1 | 2010 | 110 | 0.080 |
Why?
| | Tidal Volume | 1 | 2010 | 85 | 0.080 |
Why?
| | Positive-Pressure Respiration | 1 | 2010 | 78 | 0.080 |
Why?
| | Survival Analysis | 4 | 2017 | 1271 | 0.080 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2010 | 49 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 3 | 2008 | 2511 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2013 | 532 | 0.080 |
Why?
| | Fibroma | 1 | 2009 | 22 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 462 | 0.080 |
Why?
| | Genes, p16 | 1 | 2009 | 19 | 0.080 |
Why?
| | Cell Dedifferentiation | 1 | 2009 | 30 | 0.080 |
Why?
| | Aged, 80 and over | 6 | 2013 | 7066 | 0.080 |
Why?
| | Reproducibility of Results | 4 | 2016 | 3089 | 0.080 |
Why?
| | Carcinoma, Renal Cell | 1 | 2010 | 178 | 0.070 |
Why?
| | Tissue Fixation | 2 | 2008 | 33 | 0.070 |
Why?
| | Collagen | 1 | 2009 | 438 | 0.070 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2006 | 15 | 0.070 |
Why?
| | Cytodiagnosis | 1 | 2006 | 32 | 0.070 |
Why?
| | Forkhead Box Protein O1 | 1 | 2006 | 22 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2009 | 503 | 0.060 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2008 | 201 | 0.060 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 154 | 0.060 |
Why?
| | Kidney Neoplasms | 1 | 2010 | 347 | 0.060 |
Why?
| | Adenoma | 1 | 2008 | 213 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2062 | 0.060 |
Why?
| | Gene Rearrangement | 1 | 2006 | 148 | 0.060 |
Why?
| | Rare Diseases | 1 | 2006 | 96 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 999 | 0.060 |
Why?
| | Pain Measurement | 1 | 2008 | 510 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 443 | 0.060 |
Why?
| | Coccidioides | 1 | 2004 | 4 | 0.060 |
Why?
| | Coccidioidomycosis | 1 | 2004 | 7 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2271 | 0.060 |
Why?
| | Shoulder Pain | 1 | 2004 | 32 | 0.060 |
Why?
| | Salivary Gland Neoplasms | 1 | 2004 | 34 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1368 | 0.060 |
Why?
| | Epigenesis, Genetic | 1 | 2009 | 615 | 0.050 |
Why?
| | Taxoids | 1 | 2004 | 98 | 0.050 |
Why?
| | Mesothelioma | 1 | 2004 | 38 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 2016 | 0.050 |
Why?
| | Prognosis | 4 | 2016 | 3773 | 0.050 |
Why?
| | Osteosarcoma | 1 | 2004 | 70 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 187 | 0.050 |
Why?
| | Tissue Array Analysis | 2 | 2013 | 55 | 0.050 |
Why?
| | Sarcoma, Synovial | 1 | 2002 | 17 | 0.050 |
Why?
| | Fibroma, Desmoplastic | 1 | 2002 | 2 | 0.050 |
Why?
| | Fibroblasts | 1 | 2007 | 954 | 0.050 |
Why?
| | Artifacts | 1 | 2003 | 127 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2017 | 10241 | 0.050 |
Why?
| | Ribs | 1 | 2002 | 34 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 1951 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 766 | 0.040 |
Why?
| | Leukopenia | 2 | 2014 | 28 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 879 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 2045 | 0.040 |
Why?
| | Fowlpox virus | 1 | 2019 | 1 | 0.040 |
Why?
| | Administration, Intravesical | 1 | 2019 | 15 | 0.040 |
Why?
| | Follow-Up Studies | 3 | 2017 | 4896 | 0.040 |
Why?
| | Paraffin Embedding | 2 | 2010 | 29 | 0.040 |
Why?
| | Incidence | 2 | 2017 | 2646 | 0.040 |
Why?
| | Phosphorylation | 2 | 2013 | 1716 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2006 | 1514 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 954 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2006 | 1274 | 0.040 |
Why?
| | International Agencies | 1 | 2016 | 29 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1686 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2019 | 379 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 377 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2016 | 74 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1311 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2010 | 1847 | 0.030 |
Why?
| | Chemotherapy-Induced Febrile Neutropenia | 1 | 2014 | 1 | 0.030 |
Why?
| | Early Termination of Clinical Trials | 1 | 2014 | 15 | 0.030 |
Why?
| | Adolescent | 4 | 2006 | 20451 | 0.030 |
Why?
| | Patient Selection | 1 | 2017 | 660 | 0.030 |
Why?
| | Myxoma | 1 | 2013 | 12 | 0.030 |
Why?
| | Histocytochemistry | 1 | 2013 | 80 | 0.030 |
Why?
| | Alopecia | 1 | 2013 | 30 | 0.030 |
Why?
| | Carcinoma, Small Cell | 1 | 2014 | 169 | 0.030 |
Why?
| | Cohort Studies | 2 | 2014 | 5444 | 0.030 |
Why?
| | Genes, p53 | 1 | 2013 | 70 | 0.030 |
Why?
| | Chemoprevention | 1 | 2013 | 91 | 0.030 |
Why?
| | Demography | 1 | 2013 | 279 | 0.020 |
Why?
| | Tamoxifen | 1 | 2013 | 197 | 0.020 |
Why?
| | Constipation | 1 | 2013 | 88 | 0.020 |
Why?
| | Postoperative Period | 1 | 2013 | 330 | 0.020 |
Why?
| | Estrogen Receptor alpha | 1 | 2013 | 130 | 0.020 |
Why?
| | Microscopy | 1 | 2013 | 140 | 0.020 |
Why?
| | Longevity | 1 | 2013 | 155 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1368 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 380 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2013 | 931 | 0.020 |
Why?
| | Fatigue | 1 | 2013 | 319 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2014 | 546 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 851 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 610 | 0.020 |
Why?
| | Cetuximab | 1 | 2011 | 94 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2724 | 0.020 |
Why?
| | Estradiol | 1 | 2013 | 494 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2016 | 893 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2010 | 121 | 0.020 |
Why?
| | Chromosome Aberrations | 1 | 2010 | 140 | 0.020 |
Why?
| | Respiratory Mechanics | 1 | 2010 | 65 | 0.020 |
Why?
| | Homeostasis | 1 | 2013 | 605 | 0.020 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2009 | 54 | 0.020 |
Why?
| | Karyotyping | 1 | 2009 | 99 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2011 | 390 | 0.020 |
Why?
| | Child | 2 | 2006 | 20962 | 0.020 |
Why?
| | Pilot Projects | 1 | 2014 | 1597 | 0.020 |
Why?
| | Neoplasms, Adipose Tissue | 1 | 2009 | 1 | 0.020 |
Why?
| | Retinoblastoma Protein | 1 | 2009 | 53 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 1877 | 0.020 |
Why?
| | Animals | 3 | 2019 | 35409 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 950 | 0.020 |
Why?
| | Connective Tissue Cells | 1 | 2007 | 2 | 0.020 |
Why?
| | Fixatives | 1 | 2007 | 15 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 581 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 2010 | 260 | 0.020 |
Why?
| | Formaldehyde | 1 | 2007 | 59 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2007 | 185 | 0.020 |
Why?
| | Stromal Cells | 1 | 2007 | 106 | 0.020 |
Why?
| | Swine | 1 | 2010 | 761 | 0.020 |
Why?
| | Anesthesia | 1 | 2010 | 172 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2010 | 646 | 0.020 |
Why?
| | Mitochondria | 1 | 2013 | 875 | 0.020 |
Why?
| | Young Adult | 2 | 2013 | 12467 | 0.020 |
Why?
| | Specimen Handling | 1 | 2008 | 163 | 0.020 |
Why?
| | Thymus Gland | 1 | 2007 | 309 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2739 | 0.020 |
Why?
| | Coronary Vessels | 1 | 2007 | 239 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2378 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 756 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3185 | 0.020 |
Why?
| | Preoperative Care | 1 | 2008 | 337 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2009 | 417 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 836 | 0.010 |
Why?
| | Itraconazole | 1 | 2004 | 6 | 0.010 |
Why?
| | Oxygen | 1 | 2010 | 916 | 0.010 |
Why?
| | Phenotype | 1 | 2013 | 3062 | 0.010 |
Why?
| | Metacarpus | 1 | 2004 | 5 | 0.010 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2004 | 6 | 0.010 |
Why?
| | Hemodynamics | 1 | 2010 | 1094 | 0.010 |
Why?
| | Agranulocytosis | 1 | 2004 | 30 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2014 | 14553 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2009 | 1213 | 0.010 |
Why?
| | Pneumonia | 1 | 2010 | 619 | 0.010 |
Why?
| | Antifungal Agents | 1 | 2004 | 130 | 0.010 |
Why?
| | Edema | 1 | 2004 | 124 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2004 | 146 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2004 | 220 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 402 | 0.010 |
Why?
| | Skin | 1 | 2007 | 725 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 3971 | 0.010 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2002 | 43 | 0.010 |
Why?
| | Ki-67 Antigen | 1 | 2002 | 108 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2010 | 2703 | 0.010 |
Why?
| | Radiography | 1 | 2004 | 800 | 0.010 |
Why?
| | Cytokines | 1 | 2010 | 2022 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1089 | 0.010 |
Why?
| | Antigens, Neoplasm | 1 | 2002 | 308 | 0.010 |
Why?
| | Survival Rate | 1 | 2004 | 1872 | 0.010 |
Why?
| | Health Status | 1 | 2004 | 758 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4935 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2007 | 1644 | 0.010 |
Why?
| | Lung | 1 | 2010 | 3940 | 0.010 |
Why?
| | Mice | 1 | 2013 | 16983 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2002 | 1441 | 0.010 |
Why?
| | United States | 1 | 2004 | 13913 | 0.000 |
Why?
|
|
Aisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|